reports
Inventiva annonce la recommandation positive du quatrième DMC de l’étu...
Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH Le Data Monitoring Committee recommande sur la base d’une revue planifiée des données de sécurité que l’étude clinique de Phase III continue sans modification du protocole actuel.L’évaluation réalisée par le DMC est basée sur l’examen non masqué des données de sécurité provenant de plus de 900 patients randomisés dans les cohortes principale et exploratoire, incluant respectivement plus de 360 et plus de 80 patients ayant été traités pendant plus de 48 et 72...
Inventiva announces the positive recommendation of the fourth DMC of t...
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who exp...
Corbion General Shareholders Meeting approves Board (re)appointments a...
Corbion General Shareholders Meeting approves Board (re)appointments and dividend The annual Corbion General Shareholders Meeting held on 15 May 2024 approved the reappointment of Ilona Haaijer and Steen Riisgaard as members of the Supervisory Board. Peter Kazius was appointed as CFO. He will succeed Eddy van Rhede van Kloot, and will form the Board of Management together with CEO Olivier Rigaud. At the shareholders meeting the proposed dividend of € 0.61 per ordinary share for the financial year 2023 was also approved. Dividends will be all-cash and will in principle be subject to Dutch ...
- Guy Sips
- Jacob Mekhael
- Sharad Kumar S.P
- Wim Hoste
- Jacob Mekhael
Inventiva Additional NATIVE data supportive of lanifibranor's benefit ...
Yesterday, Inventiva announced the publication of additional results from the phase 2 (NATIVE) trial of lanifibranor in MASH (previously NASH), which are in line with previously reported benefits on cardiometabolic outcomes, leading the stock to trade +7% intraday. We believe the results continue to support lanifibranor's positioning in MASH, and look forward to the last patient first visit (expected by 1H24) in the phase 3 (NATiV3) trial. We reiterate our BUY rating and € 10 TP.
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
Inventiva announces the publication in Nature Communications of additi...
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.Among the patients who had prediabetes at study entry and were treate...
Inventiva annonce la publication dans Nature Communications de résulta...
Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité Des améliorations ont été observées au niveau de la résistance à l'insuline (taux d'insuline, HOMA-IR), du métabolisme lipidique (triglycérides, HDL-cholestérol, apolipoprotéines), du contrôle de la glycémie (HbA1c, taux de glucose à jeun), de l'inflammation systémique (hs-CRP, ferritine), de la stéatose hépatique et de la pression artérielle diastolique...
Corbion reports the progress of its € 20 million share buyback program...
Corbion reports the progress of its € 20 million share buyback program 6 May – 10 May 2024 Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024. During the week of 6 May up to and including 10 May 2024 a total of 56,299 shares were repurchased at an average price of €21.3620 for a total amount of €1,202,658.73. To date, the total consideration for shares repurchased amounts to €1,999,484.52 representing 10.00% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the pr...
Corbion reports the progress of its € 20 million share buyback program...
Corbion reports the progress of its € 20 million share buyback program 29 April – 3 May 2024 Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024. During the week of 29 April up to and including 3 May 2024 a total of 38,702 shares were repurchased at an average price of €20.5887 for a total amount of €796,825.79. To date, the total consideration for shares repurchased amounts to €796,825.79 representing 3.98% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the pro...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Laura Roba
Hyloris Pharma - Shares suspended pending 2023 audit and forensic revi...
KPMG informed the Audit committee that additional work is required to finalize the 2023 audit. They initiated a forensic independent review regarding the Qliniq transaction, including internal communication and documentation practices. Pending the review, shares will remain suspended.The Company does not expect to change the restated accounting treatment related to the Qliniq transactions.TP and BUY rating reiterated as we believe the current share price is not fully reflective of the pipeline p...
- Martin Marandon-Carlhian
- Stephane Houri
ATO ATOS SE
BFIT BASIC-FIT NV
LPE LAURENT-PERRIER SA
ACX ACERINOX SA
DEQ DEUTSCHE EUROSHOP AG
SHA SCHAEFFLER AG
FAE FAES FARMA S.A.
AIXA AIXTRON SE
WAF SILTRONIC AG
GCO GRUPO CATALANA OCCIDENTE S.A.
CSM CORBION NV
COFA COFACE SA
CASH PROSEGUR CASH SA
ALFEN ALFEN NV
FUR FUGRO NV
- Martin Marandon-Carlhian
- Stephane Houri
ATO ATOS SE
BFIT BASIC-FIT NV
LPE LAURENT-PERRIER SA
ACX ACERINOX SA
DEQ DEUTSCHE EUROSHOP AG
SHA SCHAEFFLER AG
FAE FAES FARMA S.A.
AIXA AIXTRON SE
WAF SILTRONIC AG
GCO GRUPO CATALANA OCCIDENTE S.A.
CSM CORBION NV
COFA COFACE SA
CASH PROSEGUR CASH SA
ALFEN ALFEN NV
FUR FUGRO NV
- Robert Jan Vos
Corbion N.V. : A decent Q1 2024 update; reiterated guidance could be r...
>Sales a notch below forecast, and EBITDA a tad higher than expected in Q1 - In its core operations, Corbion reported sales of € 301m and adjusted EBITDA of € 41.4m in Q1 2024. Reported sales were little lower than our forecast and consensus, but adjusted EBITDA came in slightly higher than expected, implying that EBITDA profitability of 13.8% was higher than our forecast (13.4%) and consensus (13.1%). Volume/mix growth was 1.7% (ABNe: 0.5%) and price had a negative i...
- Anthony Dick
- Michael Foundoukidis
ODDO BHF Small & MIDCAP MORNING NEWS - 04/26/2024 Date Performance sin...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
PROX PROXIMUS SA DE DROIT PUBLIC
SOP SOPRA STERIA GROUP SA
BFIT BASIC-FIT NV
NXI NEXITY SA CLASS A
MF WENDEL SE
SBS STRATEC SE
KORI KORIAN SA
STF STEF
ALCLA CLASQUIN SA
ASY ASSYSTEM SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
SRP SRP GROUPE SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
TIETO TIETOEVRY OYJ
ARCAD ARCADIS NV
SESL SES-IMAGOTAG SA
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
CSM CORBION NV
VLTSA VOLTALIA
IBG IBERPAPEL GESTION S.A.
TEC TECHNIPFMC PLC
FTG111 FLATEXDEGIRO AG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
GRP GREENCOAT RENEWABLES
- Anthony Dick
- Michael Foundoukidis
ODDO BHF Small & MIDCAP MORNING NEWS - 26/04/2024
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
PROX PROXIMUS SA DE DROIT PUBLIC
SOP SOPRA STERIA GROUP SA
BFIT BASIC-FIT NV
NXI NEXITY SA CLASS A
MF WENDEL SE
SBS STRATEC SE
KORI KORIAN SA
STF STEF
ALCLA CLASQUIN SA
ASY ASSYSTEM SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
SRP SRP GROUPE SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
TIETO TIETOEVRY OYJ
ARCAD ARCADIS NV
SESL SES-IMAGOTAG SA
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
CSM CORBION NV
VLTSA VOLTALIA
IBG IBERPAPEL GESTION S.A.
TEC TECHNIPFMC PLC
FTG111 FLATEXDEGIRO AG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
GRP GREENCOAT RENEWABLES
- Robert Jan Vos
Corbion N.V. : Decent sales/EBITDA; € 0.10 special dividend and € 20m ...
>EBITDA in line with estimates; € 0.10 special dividend; € 20m share buyback - Corbion reported net sales of € 301m and adjusted EBITDA of € 41.4m in its core operations in Q1 2024. Our forecasts were € 306m and € 41m, respectively. Consensus was at € 309m and € 40m, respectively. Sales from the PLA joint venture amounted to € 31.6m and adjusted EBITDA came in at € 4.9m, both higher than our forecasts (€ 29.6m and € 4.7m, respectively) and consensus (€ 28.6m and € 4.6...
- ING Helpdesk
Benelux Morning Notes
Basic-Fit: 1Q24 update in line, FY24 outlook in line with consensus at mid-point. bpost: Agreement on Flemish newspaper delivery; risk of provisions largely removed. Cofinimmo: Q1 results in line. Corbion: Tail wags the dog. IMCD: The last hurdle was a harsh clip. Proximus: Strong start to the year, guidance unchanged ahead of Digi arrival. Recticel: Kingspan 1Q24 trading update. Signify: 1Q24 results; revenue decline accelerates. Umicore: Confirms FY 2024 EBITDA guidance range. ...
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.